+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Análisis coste-utilidad de las bombas de insulina frente a múltiples dosis diarias en pacientes con diabetes mellitus tipo 1 en España Translated title: Cost-Utility Analysis of Iinsulin Pumps Compared to Multiple Daily doses of Insulin in Patients with Type 1 Diabetes Mellitus in Spain

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Fundamento: El uso de bombas de infusión continua de insulina (BICI) para la diabetes mellitus tipo 1 (DM1) se ha relacionado con un mejor control metabólico al compararlo con las múltiples dosis de insulina (MDI). Este mejor control puede traducirse en una disminución de las complicaciones asociadas a la DM1 y por lo tanto una reducción de los costes asociados. Sin embargo el uso de esta terapia ha quedado mermado, al menos en parte, debido a su mayor coste inicial de adquisición. El objetivo del presente estudio fue estimar las consecuencias clínicas y económicas del uso de BICI frente a MDI a través de un análisis de coste-utilidad. Métodos: Se adaptó un modelo matemático de simulación que emplea datos clínicos y económicos de ámbito nacional, para simular las consecuencias clínicas y económicas a largo plazo de un paciente con DM1. El horizonte temporal fue el de toda la vida del paciente, incluyendo sólo costes directos sanitarios, y actualizando tanto costes como beneficios a una tasa del 3% anual. Resultados: En el caso base los pacientes tratados con BICI experimentaron una ganancia de vida de 0,890 años (p<0,05) y 0,852 AVACs (p<0,05). El tratamiento con BICI produce un coste medio incremental de 25.523 € (p<0,05) por paciente tratado, lo que nos condujo a un ratio coste- utilidad incremental de 29.947 €/AVAC [IC 95% (29.519, 30.375)]. Conclusiones: La mejora en el control glucémico en pacientes con BICI se asoció a una reducción del coste global del manejo de pacientes con DM1, y resultó tener una relación coste-utilidad favorable al compararla con el tratamiento convencional MDI.

          Translated abstract

          Background: The use of continuous subcutaneous insulin infusion (CSII) for treating Type I diabetes mellitus (DM1) has been related to better metabolic control compared it to daily multiple insulin injections (DMI) and thus to a lowering of the related costs. However, this therapy is now being used to a lesser extent due, at least partially, to the higher initial cost of purchase. This study is aimed at estimating the clinical and economic consequences of using CSII as compared to DMI by means of a cost-utility analysis. Methods: A mathematical simulation model was adapted using nationwide clinical and economic data to simulate the long-term clinical and economic consequences for a DM1 patient. The time horizon was the patient's lifetime, including only direct healthcare costs and updating both costs and benefits at an annual 3% rate. Results: In the basecase, the patients treated using CSII gained 0.890 years (p<0.05) and 0.852 QALYs (p<0.05). CSII treatment gives rise to an incremental average cost of 25,523 € (p<0.05) per patient treated, which gave us an incremental cost- utility ratio of 29,947 €/QALY [CI 95% (29,519; 30,375)]. Conclusions: The improvement in the glucose control among those patients treated using CSII was related to an overall lower cost in the handling of DM1 patients, which was found to have a favourable cost-utility ratio in comparison to conventional MDI treatment.

          Related collections

          Most cited references 43

          • Record: found
          • Abstract: found
          • Article: not found

          Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

          To determine the relation between systolic blood pressure over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes. Prospective observational study. 23 hospital based clinics in England, Scotland, and Northern Ireland. 4801 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of relative risk. Primary predefined aggregate clinical outcomes: any complications or deaths related to diabetes and all cause mortality. Secondary aggregate outcomes: myocardial infarction, stroke, lower extremity amputation (including death from peripheral vascular disease), and microvascular disease (predominantly retinal photocoagulation). Single end points: non-fatal heart failure and cataract extraction. Risk reduction associated with a 10 mm Hg decrease in updated mean systolic blood pressure adjusted for specific confounders. The incidence of clinical complications was significantly associated with systolic blood pressure, except for cataract extraction. Each 10 mm Hg decrease in updated mean systolic blood pressure was associated with reductions in risk of 12% for any complication related to diabetes (95% confidence interval 10% to 14%, P<0.0001), 15% for deaths related to diabetes (12% to 18%, P<0.0001), 11% for myocardial infarction (7% to 14%, P<0.0001), and 13% for microvascular complications (10% to 16%, P<0.0001). No threshold of risk was observed for any end point. In patients with type 2 diabetes the risk of diabetic complications was strongly associated with raised blood pressure. Any reduction in blood pressure is likely to reduce the risk of complications, with the lowest risk being in those with systolic blood pressure less than 120 mm Hg.
            • Record: found
            • Abstract: found
            • Article: not found

            One thousand health-related quality-of-life estimates.

            Analysts performing cost-effectiveness analyses often do not have the resources to gather original quality-of-life (QOL) weights. Furthermore, variability in QOL for the same health state hampers the comparability of cost-effectiveness analyses. For these reasons, opinion leaders such as the Panel on Cost-Effectiveness in Health and Medicine have called for a national repository of QOL weights. Some authors have responded to the call by performing large primary studies of QOL. We take a different approach, amassing existing data with the hope that it will be combined responsibly in meta-analytic fashion. Toward the goal of developing a national repository of QOL weights to aid cost-effectiveness analysts, 1,000 health-related QOL estimates were gathered from publicly available source documents. To identify documents, we searched databases and reviewed the bibliographies of articles, books, and government reports. From each document, we extracted information on the health state, QOL weight, assessment method, respondents, and upper and lower bounds of the QOL scale. Detailed guidelines were followed to ensure consistency in data extraction. We identified 154 documents yielding 1,000 original QOL weights. There was considerable variation in the weights assessed by different authors for the same health state. Methods also varied: 51% of authors used direct elicitation (standard gamble, time tradeoff, or rating scale), 32% estimated QOL based on their own expertise or that of others, and 17% used health status instruments. This comprehensive review of QOL data should lead to more consistent use of QOL weights and thus more comparable cost-effectiveness analyses.
              • Record: found
              • Abstract: not found
              • Article: not found

              Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus

               rch Group (2002)

                Author and article information

                Revista Española de Salud Pública
                Rev. Esp. Salud Publica
                Ministerio de Sanidad, Consumo y Bienestar social (Madrid, Madrid, Spain )
                December 2006
                : 80
                : 6
                : 679-695
                orgnameHospital Clínic i Universitari orgdiv1Servicio de Endocrinología y Diabetes
                Barcelona orgnameInstitut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) España
                Basilea orgnameCenter for Outcomes Research (CORE) Suiza
                Madrid orgnameMedtronic Ibérica orgdiv1Economía de la Salud y Reembolso España
                orgnameGeneralitar de Catalunya orgdiv1Direcció General de Salut Pública orgdiv2Departament de Salut España
                S1135-57272006000600008 S1135-5727(06)08000600008

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 International License.

                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 58, Pages: 17
                Product Information: website


                Comment on this article